betamethasone - Profile

What are the generic sources for betamethasone and what is the scope of patent protection?

Betamethasone is the generic ingredient in twenty-six branded drugs marketed by Schering, Merck Sharp Dohme, Am Regent, Hikma, Organon, Parke Davis, Chartwell Molecular, Fougera Pharms, Glenmark Pharms Inc, Padagis Israel, Sun Pharma Canada, Savage Labs, Actavis Mid Atlantic, Aurobindo Pharma Ltd, Cosette, Perrigo New York, Pharmaderm, Teva, Zydus Pharms, Encube, Alpharma Us Pharms, Fougera Pharms Inc, Padagis Us, Shree Hari Intl, Lupin Ltd, Tp Anda Holdings, Zydus Lifesciences, Primus Pharms, Glenmark Pharms Ltd, Leo Pharma As, MC2, Chartwell Rx, Glenmark Speclt, Taro, Watson Labs, Alembic, Novast Labs, Xiromed, Pharmobedient, Roaco, Pharmafair, Senores Pharms, and Teva Pharms, and is included in one hundred and twenty-three NDAs. There are eighteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Summary for betamethasone

US Patents:	18
Tradenames:	26
Applicants:	43
NDAs:	123

US Patents and Regulatory Information for betamethasone

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Schering	CELESTONE	betamethasone	CREAM;TOPICAL	014762-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Merck Sharp Dohme	CELESTONE	betamethasone	SYRUP;ORAL	014215-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Schering	CELESTONE	betamethasone	TABLET;ORAL	012657-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Am Regent	BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE	betamethasone acetate; betamethasone sodium phosphate	INJECTABLE;INJECTION	090747-001	Jul 31, 2009	AB	RX	No	No

Expired US Patents for betamethasone

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Schering	CELESTONE	betamethasone	CREAM;TOPICAL	014762-001	Approved Prior to Jan 1, 1982	3,485,854
Merck Sharp Dohme	CELESTONE	betamethasone	SYRUP;ORAL	014215-002	Approved Prior to Jan 1, 1982	3,485,854
Schering	CELESTONE	betamethasone	TABLET;ORAL	012657-003	Approved Prior to Jan 1, 1982	3,485,854

Betamethasone: Investment Scenario and Fundamentals Analysis

Last updated: February 22, 2026

What is Betamethasone?

Betamethasone is a synthetic glucocorticoid used mainly for its anti-inflammatory and immunosuppressive properties. It is available in various formulations, including injectable, topical, and oral forms. Its primary therapeutic indications include allergic skin conditions, inflammation, autoimmune diseases, and respiratory disorders.

Market Overview

The global corticosteroids market, including betamethasone, was valued at approximately USD 2.7 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 4.2% from 2023 to 2030. Demand is driven by increased prevalence of autoimmune diseases, allergies, and respiratory conditions, along with expanding use of steroids in biosimilar and generic markets.

Key Players and Supply Chain

Major manufacturers comprise:

• Teva Pharmaceutical Industries
• Sandoz (Novartis)
• Mylan
• Sun Pharmaceutical Industries
• Pfizer

Generic versions of betamethasone dominate the market, with patent protections mainly on specific formulations or delivery mechanisms. Raw material sourcing involves licensed production of corticosteroid intermediates, often focusing on synthetic steroids derived from plant-based precursors.

Patent Landscape and Regulatory Status

Betamethasone's patents largely expired or are nearing expiry, facilitating generic market entry. Regulatory approvals are held across global agencies, including the FDA and EMA, for approved indications in various formulations.

The drug's regulatory barriers are generally low for generic manufacturing but include quality controls for bioequivalence, batch consistency, and safety profiles.

Investment Considerations

Market Dynamics

• Demand Drivers: Rise in autoimmune diseases, respiratory illnesses, and allergy-related conditions.
• Competition: High; dominated by generics with minimal patent protections.
• Pricing Trends: Decreasing due to market saturation and generic competition.

R&D and Innovation

Recent innovation efforts focus on enhanced formulations, such as long-acting injections or combination therapies. However, substantial R&D investment for new indications is limited, given the drug's established status.

Regulatory Environment

Approval pathways for generics are well-established. Barriers include stringent quality storage rules and evolving biosimilar regulations, but these do not significantly hinder market entry.

Patent Expiry and Market Entry

Most patents for betamethasone formulations expired between 2018 and 2022, creating opportunities for generic manufacturers in both developed and emerging markets.

Risks

• Price erosion due to increased competition.
• Regulatory scrutiny over manufacturing quality.
• Generic market saturation leading to reduced profit margins.

Investment Outlook

Investments in betamethasone-centric assets should focus on:

1. Generic Production: Companies with validated manufacturing processes can capitalize on market saturation.
2. Formulation Innovation: Niche markets for long-acting or combination formulations.
3. Emerging Markets: Regions with less stringent regulations present growth opportunities.

Financial Performance and Valuation Metrics

Most betamethasone products generate low-margin revenues driven by high-volume sales. Profitability depends on manufacturing efficiency and market penetration.

Valuations are typically based on:

• Revenue growth potential
• Patent expiry timelines
• Cost of manufacturing
• Competitive dynamics

Key Takeaways

• Betamethasone's market is mature, with significant generic penetration.
• Patent expiries have opened markets for new entrants, but margins are compressed.
• Demand remains steady due to chronic condition treatment.
• Innovation in formulations offers limited but potentially lucrative opportunities.
• Risks include market saturation and price competition.

FAQs

1. When are the major patent expiries for betamethasone?
Most betamethasone patents expired between 2018 and 2022, enabling generic competition globally.

2. Which formulations dominate the market?
Topical creams and injectable forms account for majority sales, with oral tablets holding a smaller share.

3. Are biosimilars relevant for betamethasone?
No. Since betamethasone is a small molecule steroid, biosimilar pathways do not apply; generics are the primary competitive segment.

4. What regions offer the highest growth potential?
Emerging markets in Asia, Latin America, and Africa, where regulatory barriers are lower, present expansion opportunities.

5. What are the key risk factors for investors?
Market saturation, declining prices, and regulatory compliance costs pose principal risks.

References

1. MarketResearch.com. (2022). Corticosteroids Market Size and Share Analysis.
2. U.S. Food and Drug Administration. (2022). Approved Drugs Database.
3. European Medicines Agency. (2022). Market Authorizations for Steroids.
4. IQVIA. (2022). Global Pharmaceutical Market Analysis Report.
5. GlobalData. (2023). Biosimilars and Small Molecule Steroid Market Forecast.